Business Description
Chugai Pharmaceutical Co Ltd
ISIN : JP3519400000
Share Class Description:
CHGCF: Ordinary SharesTotal Employee Number:
7,872Description
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.83 | |||||
Interest Coverage | 4216.44 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 18.61 | |||||
Beneish M-Score | -2.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.1 | |||||
3-Year EBITDA Growth Rate | 4 | |||||
3-Year EPS without NRI Growth Rate | 12.4 | |||||
3-Year FCF Growth Rate | 16.8 | |||||
3-Year Book Growth Rate | 12.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 15.65 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.94 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.61 | |||||
9-Day RSI | 47.33 | |||||
14-Day RSI | 47.24 | |||||
3-1 Month Momentum % | -17.01 | |||||
6-1 Month Momentum % | -22.47 | |||||
12-1 Month Momentum % | -11.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.35 | |||||
Quick Ratio | 3.54 | |||||
Cash Ratio | 2.45 | |||||
Days Inventory | 258.87 | |||||
Days Sales Outstanding | 100.46 | |||||
Days Payable | 104.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.99 | |||||
Dividend Payout Ratio | 0.47 | |||||
3-Year Dividend Growth Rate | 16.1 | |||||
Forward Dividend Yield % | 2 | |||||
5-Year Yield-on-Cost % | 4.22 | |||||
Shareholder Yield % | 1.98 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.34 | |||||
Operating Margin % | 48.04 | |||||
Net Margin % | 35.1 | |||||
EBITDA Margin % | 48.8 | |||||
FCF Margin % | 27.48 | |||||
OCF Margin % | 33.25 | |||||
ROE % | 23.96 | |||||
ROA % | 20.24 | |||||
ROIC % | 38.48 | |||||
3-Year ROIIC % | 27.7 | |||||
ROC (Joel Greenblatt) % | 78.92 | |||||
ROCE % | 32.83 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 23.48 | |||||
Forward PE Ratio | 22.25 | |||||
PE Ratio without NRI | 23.35 | |||||
Shiller PE Ratio | 38.21 | |||||
Price-to-Owner-Earnings | 33.31 | |||||
PEG Ratio | 1.9 | |||||
PS Ratio | 8.05 | |||||
PB Ratio | 5.32 | |||||
Price-to-Tangible-Book | 5.48 | |||||
Price-to-Free-Cash-Flow | 29.02 | |||||
Price-to-Operating-Cash-Flow | 24.02 | |||||
EV-to-EBIT | 14.3 | |||||
EV-to-Forward-EBIT | 15.49 | |||||
EV-to-EBITDA | 14.3 | |||||
EV-to-Forward-EBITDA | 14.87 | |||||
EV-to-Revenue | 6.98 | |||||
EV-to-Forward-Revenue | 7.69 | |||||
EV-to-FCF | 25.38 | |||||
Price-to-GF-Value | 0.91 | |||||
Price-to-Projected-FCF | 2.05 | |||||
Price-to-DCF (Earnings Based) | 0.61 | |||||
Price-to-DCF (FCF Based) | 0.79 | |||||
Price-to-Median-PS-Value | 1.15 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.55 | |||||
Price-to-Graham-Number | 2.36 | |||||
| Price-to-Net-Current-Asset-Value | 8.42 | |||||
| Price-to-Net-Cash | 19.99 | |||||
Earnings Yield (Greenblatt) % | 6.99 | |||||
FCF Yield % | 3.59 | |||||
Forward Rate of Return (Yacktman) % | 11.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CHGCF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chugai Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8,626.652 | ||
| EPS (TTM) ($) | 1.839 | ||
| Beta | 0.1519 | ||
| 3-Year Sharpe Ratio | 0.44 | ||
| 3-Year Sortino Ratio | 0.74 | ||
| Volatility % | 43.48 | ||
| 14-Day RSI | 47.24 | ||
| 14-Day ATR ($) | 3.315282 | ||
| 20-Day SMA ($) | 44.129375 | ||
| 12-1 Month Momentum % | -11.25 | ||
| 52-Week Range ($) | 39.03 - 68.0775 | ||
| Shares Outstanding (Mil) | 1,645.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chugai Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chugai Pharmaceutical Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-01-29 18:00 | In 182 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-29 17:00 | In 182 days | ||
| JPY 66.000000 Cash Dividend | 2026-12-31 | In 152 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-27 18:00 | In 88 days | ||
| Third quarter earnings results for 2026 | 2026-10-27 17:00 | In 88 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 17:00 | 41.68 (-2.25%) | ||
| Second quarter earnings results for 2026 | 2026-07-24 16:00 | 41.68 (-2.25%) | ||
| JPY 66.000000 Cash Dividend | 2026-06-30 | 48.21 (+5.75%) | ||
| First quarter earnings conference call for 2026 | 2026-04-24 18:00 | 57.30 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-24 17:00 | 57.30 (+0.00%) |
Show
Entries
Chugai Pharmaceutical Co Ltd Frequently Asked Questions
What is Chugai Pharmaceutical Co Ltd(CHGCF)'s stock price today?
The current price of CHGCF is $43.18. The 52 week high of CHGCF is $68.08 and 52 week low is $39.03.
When is next earnings date of Chugai Pharmaceutical Co Ltd(CHGCF)?
The next earnings date of Chugai Pharmaceutical Co Ltd(CHGCF) is 2026-10-27.
Does Chugai Pharmaceutical Co Ltd(CHGCF) pay dividends? If so, how much?
The Dividend Yield %  of Chugai Pharmaceutical Co Ltd(CHGCF) is 1.99% (As of Today), Highest Dividend Payout Ratio of Chugai Pharmaceutical Co Ltd(CHGCF) was 0.53. The lowest was 0.31. And the median was 0.41. The  Forward Dividend Yield % of Chugai Pharmaceutical Co Ltd(CHGCF) is 2%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on OTCPK:CHGCF
No articles.
Press Release
Articles on Chugai Pharmaceutical Co Ltd
Headlines
See More- 1
Jul 24, 2026
Chugai Pharmaceutical reports 1H results
Seeking Alpha • 4:06am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers